M
M. Botia
Publications - 3
Citations - 492
M. Botia is an academic researcher. The author has contributed to research in topics: Lung cancer & Cisplatin. The author has an hindex of 3, co-authored 3 publications receiving 489 citations.
Papers
More filters
Journal ArticleDOI
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla,Carme Sarries,Rafael Rosell,Guillermo Alonso,Manuel Domine,Miquel Taron,Guillermo Lopez-Vivanco,Carlos Camps,M. Botia,L. Nuñez,Maria Sanchez-Ronco,Jose Javier Sanchez,Marta López-Brea,Isidoro Barneto,A. Paredes,B. Medina,Angel Artal,Pilar Lianes +17 more
TL;DR: ERCC1 SNP assessment could be an important component of tailored chemotherapy trials and patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival.
Journal ArticleDOI
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
R. de las Peñas,Maria Sanchez-Ronco,Vicente Alberola,Miquel Taron,Carlos Camps,R. Garcia-Carbonero,B. Massuti,Cristina Queralt,M. Botia,Ramon Garcia-Gomez,Dolores Isla,M. Cobo,Mariacarmela Santarpia,F.L. Cecere,Pedro Mendez,Jose Javier Sanchez,Rafael Rosell +16 more
TL;DR: A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy and is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine.
Serum DNA as a tool for cancer patient management.
Jose Luis Ramirez,Miquel Taron,Carmen Balana,Carme Sarries,Pedro Mendez,de Aguirre I,L. Nuñez,Roig B,Cristina Queralt,M. Botia,Rafael Rosell +10 more
TL;DR: The study of serum or plasma DNA has opened new roads for translational research and new strategies for molecular diagnosis and can be used to calculate the risk of local or distant recurrence and its relationship with survival and its value in patient follow-up to evaluate response to therapy.